Aldose Reductase Inhibitor Probenecid Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetic complications, such as diabetic cardiomyopathy, often rely on individual aldose reductase inhibitors (ARIs) with short plasma half-lives, which may require frequent dosing and have limited cardiovascular benefits, while probenecid shows promise for cardiac function improvement but lacks comprehensive combination therapy data with ARIs.
Innovation Solution
Development of pharmaceutical compositions combining ARIs like AT-001, AT-003, AT-007, zopolrestat, and epalrestat with probenecid, expanding their cardiovascular benefits and potentially extending the plasma half-life of shorter-lived ARIs, thereby enhancing therapeutic efficacy for diabetic complications like diabetic cardiomyopathy, neuropathy, and retinopathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If individual aldose reductase inhibitors (ARIs) are used for treating diabetic complications, then the treatment targets specific diabetic complications, but the plasma half-life is short requiring frequent dosing
Solution Approach 1:
The patent combines an ARI with probenecid in a single pharmaceutical composition. Probenecid is known to inhibit renal excretion of certain drugs, and when combined with ARI, it extends the plasma half-life of the ARI component, thereby reducing dosing frequency while maintaining therapeutic efficacy.
2Reliability
If individual aldose reductase inhibitors (ARIs) are used for treating diabetic complications, then the mechanism of action is specific, but the cardiovascular benefits are limited
Solution Approach 1:
The combined pharmaceutical composition provides multiple therapeutic benefits: the ARI component addresses diabetic complications through aldose reductase inhibition, while probenecid contributes cardiovascular protective effects and extends drug half-life. This multi-functional approach enhances both reliability and adaptability of the treatment.
3Duration of action of moving object
If probenecid is combined with ARIs, then the plasma half-life of ARIs is extended, but the combination therapy data is limited
Solution Approach 1:
The patent performs preliminary preclinical studies in animal models to establish the safety and efficacy of the ARI-probenecid combination before clinical application. This preliminary action generates reliable data on pharmacokinetic interactions and therapeutic effects, reducing uncertainty about combination therapy efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy provides enhanced cardiovascular benefits, potentially improving cardiac output and left ventricular ejection fraction, and may require less frequent dosing due to extended half-life, addressing the limitations of individual ARI treatments.
Implementation Method 1
The concomitant oral administration of probenecid increases the mean plasma elimination half-life of certain carboxylic acid (anionic) therapeutic agents such as penicillin when administered either orally or parenterally. The renal excretion of such carboxylic acid drugs is reduced due to probenecid.
Implementation Method 2
Aldose reductase inhibitors (ARIs) function by inhibiting the activity of the enzyme aldose reductase, which is primarily responsible for regulating the reduction of aldoses, such as glucose and galactose, to the corresponding polyols, such as sorbitol and galactitol, in humans and other animals.
Data Source
AI summary
The subject invention provides pharmaceutical compositions comprising combinations of probenecid or a pharmaceutically acceptable salt thereof, and one or more carboxylic acid aldose reductase inhibitors (ARIs) or pharmaceutically acceptable salts thereof. The subject invention also provides methods of using such combinations to treat mammals, including humans, suffering from diabetic complications such as, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cataracts, diabetic cardiovascular complications, including cardiomyopathy, myocardial infarction, heart failure and atherosclerosis and non-diabetic cardiovascular complications, including myocardial infarction, coronary artery disease, atherosclerotic cardiovascular diseases and heart failure.